Research / AHT / Fundamental state Inspectable configuration
State dimensions Filing 0001232582-22-000077 Reit
Debt 22th Own-history percentile · N=18
Evidence method Level · gp.fundamentals.gross_debt
$3.8B · CORE · VALID
Revenue growth 67th Own-history percentile · N=9
Evidence method Yoy · gp.fundamentals.revenue
79.98% · CORE · VALID
Cash and equivalents 83th Own-history percentile · N=18
Evidence method Level · gp.fundamentals.cash
$537.8M · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 26 states Self-history eligible
Sep 30, 2021 2/3 normalized Level 3 Dec 31, 2021 2/3 normalized Level 3 Mar 31, 2022 3/3 normalized Level 3 Jun 30, 2022 3/3 normalized Level 3 Sep 30, 2022 4/4 normalized Level 3 Dec 31, 2022 3/3 normalized Level 3 Mar 31, 2023 3/3 normalized Level 3 Jun 30, 2023 5/5 normalized Level 3 Sep 30, 2023 5/5 normalized Level 3 Dec 31, 2023 5/5 normalized Level 3 Mar 31, 2024 5/5 normalized Level 3 Jun 30, 2024 5/5 normalized Level 3 Sep 30, 2024 5/5 normalized Level 3 Dec 31, 2024 5/5 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 5/6 normalized Level 3 Sep 30, 2025 5/5 normalized Level 3 Dec 31, 2025 4/4 normalized Level 3 Mar 31, 2026 4/4 normalized Level 3 Jun 30, 2026 5/5 normalized Level 4 Period transition
What moved in the state? Debt Decreased
Previous $3.9B
Current $3.8B
Delta -$39.5M Growth Decreased
Previous 113.36%
Current 79.98%
Delta -33.39% Liquidity Decreased
Previous $548.6M
Current $537.8M
Delta -$10.8M Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.